New drug development in the United States from 1963 to 1999

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 5, 2001, Pages 286-296

  DiMasi, Joseph A ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; MONOCLONAL ANTIBODY; NEW DRUG; POLYCLONAL ANTIBODY; RECOMBINANT DNA;

DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; PRIORITY JOURNAL; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES;

EID: 0035336557     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.115132     Document Type: Note

References (29)

1. Dubois RW, Chawla AJ, Neslusen CA, Smith MW, Wade S. Explaining drug spending trends: Does perception match reality? Health Aff(Millwood) 2000;19:231-9.
2. US House of Representatives, Committee on Government Reform, Special Investigations Division, Minority Staff. Prescription Drug Pricing in the United States: Drug Companies Profit at the Expense of Older Americans. Report prepared for Representative Henry A. Waxman, Washington DC, 1999. Available from: www.house.gov/Berry/Prescription Drugs/Resources/GR1199Natldrug.pdf.
3. Huskamp HA, Rosenthal MB, Frank RG, Newhouse JP. The medicare prescription drug benefit: How will the game be played? Health Aff (Millwood) 2000;19:8-23.
4. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991;10:107-42.
5. DiMasi JA, Grabowski HG, Vernon J. R&D costs, innovative output, and firm size in the pharmaceutical industry. Int J Econ Bus 1995;2:201-19.
6. Drews J, Reyser S. Innovation deficit in the pharmaceutical industry. Drug Inf J 1996;30:97-108.
7. DiMasi JA. New drug innovation and pharmaceutical industry structure: Trends in the output of pharmaceutical firms. Drug Inf J 2000;34:1169-94.
8. Drews J. In Quest of Tomorrow's Medicines. New York: Springer; 1999.
9. Prescription Drug User Fee Act of 1992. Pub. L. No. 102-571, 106 Stat, 4491; pt 29;21 USC 379 (Oct 29, 1992).
10. Kaitin KI, Healy EM. The new drug approvals of 1996, 1997, and 1998: Drug development trends in the user fee era. Drug Inf J 2000;34:1-14.
11. Kaitin KI, DiMasi JA. Measuring the pace of new drug development in the user fee era. Drug Inf J 2000;34: 673-80.
12. Food and Drug Administration Modernization Act of 1997. Pub. L. 105-115, 111 Stat. 2296; 21 USC 355a (Nov 21, 1997).
13. Wardell WM, Hassar M, Anavekar SN, Lasagna L. The rate of development of new drugs in the United States, 1963 through 1975. Clin Pharmacol Ther 1978;24:133-45.
14. Wardell WM, DiRaddo J, Trimble AG. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-1976. Clin Pharmacol Ther 1980;28:270-7.
15. Wardell WM, May MS, Trimble AG. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979. Clin Pharmacol Ther 1982;32: 407-17.
16. May MS, Wardell WM, Lasagna L. New drug development during and after a period of regulatory change: Clinical research activity of major United States pharmaceutical firms, 1958 to 1979. Clin Pharmacol Ther 1983; 33:691-700.
17. Mattison N, Trimble AG, Lasagna L. New drug development in the United States, 1963 through 1984. Clin Pharmacol Ther 1988;43:290-301.
18. DiMasi JA, Bryant NR, Lasagna L. New drug development in the United States from 1963 to 1990. Clin Pharmacol Ther 1991;50:471-86.
19. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994;55:609-22.
20. 1962 Amendments to the Federal Food, Drug, and Cosmetic Act of 1938. Pub. L 87-781, 76 Stat. 780 (Oct 10, 1962).
21. The NDA Pipeline. Chevy Chase (MD): F-D-C Development Corp [various years]; 1982-99.
22. Office of Management, Food and Drug Administration. New Drug Evaluation Statistical Report. Rockville (MD): FDA [various years]; 1979-93.
23. Food and Drug Administration. Human drugs - Patent extension: Regulatory review period determinations. Federal Register [various Years]; 1984-99.
24. Pharma Projects. Richmond, Surrey (UK): PJB Publications; 1999.
25. Associate Director for New Drug Evaluation. Drug Classification: Staff Manual Guide. Washington (DC): Bureau of Drugs; Food and Drug Administration. BD 4820.3 (Aug 31, 1976).
26. DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 1995;58:1-14.
27. Gosse ME, DiMasi JA, Nelson TF. Recombinant proteins and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994. Clin Pharmacol Ther 1996;60:608-18.
28. FY 2000 Performance Report to Congress for the Prescription Drug User Fee Act of 1992 as Amended by the Food and Drug Administration Modernization Act of 1997. Available from: URL: http://www.fda.gov/ope/ reports.html.
29. DiMasi JA, Manocchia M. Initiatives to speed new drug development and regulatory review: The impact of FDA-sponsor conferences. Drug Inf J 1997;31:771-8.